You are here: Industry Insights > AbbVie

News List

USFDA extends review period for AbbVie’s sNDA of upadacitinib pharmaceutical-business-review
March 18, 2021
The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib.
Mitokinin Enters into Purchase Agreement with AbbVie americanpharmaceuticalreview
March 08, 2021
AbbVie has purchased an exclusive right to acquire Mitokinin following completion of IND enabling studies on Mitokinin's lead PINK1 compound.
Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie contractpharma
March 08, 2021
Pharmaron Beijing has entered into a definitive agreement to acquire Allergan Biologics Limited (ABL) in Liverpool, UK, for $118.7 million from AbbVie.
AbbVie Opts to Acquire Mitokinin contractpharma
March 03, 2021
Following completion of IND enabling studies on Mitokinin's lead PINK1 compound for Parkinson's disease.
HUMIRA Receives FDA Approval to Treat Pediatric Patients with Ulcerative Colitis americanpharmaceuticalreview
March 02, 2021
AbbVie announced the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older.
Upadacitinib meets all endpoints in Phase III ulcerative colitis trial europeanpharmaceuticalreview
February 24, 2021
In the trial, 74 percent of participants responded to upadacitinib and 33 percent of patients achieved clinical remission.
AbbVie's Rinvoq bags two new EU approvals pharmatimes
January 27, 2021
The European Commission (EC) has approved AbbVie’s Rinvoq (upadacitinib) for the treatment of active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
AbbVie Licenses ProBioGen’s GlymaxX Technology contractpharma
January 26, 2021
ProBioGen has signed a commercial license agreement with AbbVie to apply ProBioGen's GlymaxX technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC).
Drug pricing, reimbursement constraints leading impediments to industry growth in 2021: GlobalData expresspharma
January 11, 2021
In 2021, drug pricing pressure from regulators and payers will remain and aggressive negotiation tactics to drive down drug prices will continue, according to GlobalData, a data and analytics company.
Skyrizi bags positive psoriatic arthritis results pharmatimes
January 08, 2021
AbbVie and Boehringer Ingelheim’s Skyrizi (risankizumab) has scored positive top-line results from two phase III studies in adults with active psoriatic arthritis.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page